CGON: CG Oncology Therapeutics Price-to-Revenue Multiple

Corporate company logo of CG Oncology Inc (CGON)

The revenue valuation metric illustrates the dynamics of CG Oncology, Inc. (CGON), where 1225.50 is the current value of the indicator. The business faces strict FDA oversight and colossal R&D expenditures. Meanwhile, unique oncolytic viruses enable the effective destruction of bladder tumors. The transition to mass sales will create operational leverage, which will significantly optimize historical development costs.

CGON: CG Oncology Corp Price-to-Revenue Ratio 11/14/2024 - 11/17/2026

Analytical breakdowns for cgoncology.com (CGON)

- market price and analyst price targets:
Fundamental company analysis:CGON - CG Oncology Inc
Manufactured products of CG Oncology, Inc.

Investors in CG Oncology, Inc. (CGON) must understand the business's market value relative to its ability to generate cash flow. This metric is calculated as the ratio of the issuer's total market capitalization to annual sales, and an analysis of the price-to-sales ratio allows for an assessment of the uniqueness premium for oncolytic therapies amid inelastic demand for cancer treatment.

Competitors of CG Oncology, Inc.

ONC - Price to Sales|P/S Multiple HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Price to Sales|ascentage.com - P/S Multiple|Price to Sales UroGen Pharma Ltd.|BCAX: P/S Multiple|PSNL - Price-to-Revenue Coefficient|ERAS (Erasca Oncology) - P/S Multiple|P/S Multiple Delcath Systems, Inc.|Price-to-Revenue Ratio ymabs.com (YMAB)|Price-to-Revenue Ratio AURA (Aura Biosciences, Inc.)|Candel Therapeutics - Market Cap to Revenue|Accuray Inc. (ARAY) - Price to Sales|SELLAS Life Sciences Group, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio ACTU (Actuate Therapeutics, Inc.)|Citius Oncology (CTOR) - Price-to-Revenue Ratio|HURA - Price-to-Revenue Coefficient|TARA (Protara Therapeutics, Inc.) - P/S Multiple|P/S Multiple Fate Therapeutics Inc|P/S Multiple WHWK|P/S Multiple TScan Therapeutics Inc (TCRX)|Price-to-Revenue Ratio championsoncology.com CSBR|XBIT - Market Cap to Revenue|CVM - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio OSTX (OS Therapies)|RADX: P/S Multiple|Artiva Biotherapeutics Inc. - Market Capitalization-to-Revenue Ratio|ANL (Adlai Nortye) - P/S Multiple|P/S Multiple verupharma.com|Market Cap to Revenue TPST (tempesttx.com)|Market Cap to Revenue Xilio Therapeutics Inc XLO|P/S Multiple RENB (Enochian BioSciences)|Mural Bio - Price-to-Revenue Ratio|KAPA - Price-to-Revenue Ratio|OnKure Therapeutics (OKUR) - Market Cap to Revenue|GDTC: P/S Multiple|Price to Sales Curis Corp (CRIS)|APLM (apollomicsinc.com) - P/S Multiple|Market Cap to Revenue Tharimmune Corp (THAR)|P/S Multiple ADVB|GNPX - Price to Sales|Price-to-Revenue Ratio calidibio.com CLDI|SBFM - Market Cap to Revenue|XBIO - Price-to-Revenue Ratio|SLRX: Price-to-Revenue Ratio|Purple Biotech (PPBT) - Price-to-Revenue Ratio|AON - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue BGNE|P/S Multiple Checkpoint Therapeutics Inc.|P/S Multiple ELEV|Market Cap to Revenue iCAD ICAD|P/S Multiple IKNA (Ikena Oncology, Inc.)|Market Capitalization-to-Revenue Ratio NTBL|Viracta Therapeutics, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Market Cap to Revenue|Market Cap to Revenue Ascentage Pharma Group Ltd